| Literature DB >> 27500400 |
Daniel K Fowler1,2, Scott Stewart1, Steve Seredick2, Judith S Eisen2, Kryn Stankunas1, Philip Washbourne2.
Abstract
Recombination-based cloning is a quick and efficient way to generate expression vectors. Recent advancements have provided powerful recombinant DNA methods for molecular manipulations. Here, we describe a novel collection of three-fragment MultiSite Gateway cloning system-compatible vectors providing expanded molecular tools for vertebrate research. The components of this toolkit encompass a broad range of uses such as fluorescent imaging, dual gene expression, RNA interference, tandem affinity purification, chemically-inducible dimerization and lentiviral production. We demonstrate examples highlighting the utility of this toolkit for producing multi-component vertebrate expression vectors with diverse primary research applications. The vectors presented here are compatible with other Gateway toolkits and collections, facilitating the rapid generation of a broad range of innovative DNA constructs for biological research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27500400 PMCID: PMC4976983 DOI: 10.1371/journal.pone.0159277
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Overview of three-fragment MultiSite Gateway cloning and novel lentiviral destination vectors.
(A) Schematic of an LR recombination reaction and the resulting vector. Site-specific recombination events (red lines) between attR and attL sites from a 5’, middle, and 3’ entry vector with a destination vector replaces the ccdB/CmR selection cassette of the destination vector with the mobile DNA elements from the entry vectors, leaving destination vector-specific 5’ and 3’ sequences intact. (B) Schematic of lentiviral destination vectors pEpic and pEpic_Lite. attR3 and 4 sites flanking the ccdB/CmR selection cassette are positioned in an anti-sense orientation to viral RNA expression driven by a Rous sarcoma virus (RSV) promoter. pEpic_Lite lacks puromycin resistance (PuroR). LTR = long terminal repeat; RRE = Rev response element; cPPT = central polypurine tract; ccdB = E. coli ccdB toxin; CmR = chloramphenicol resistance; mPGK = mouse phosphoglycerate kinase promoter; WPRE = woodchuck hepatitis virus posttranslational regulatory element.
Entry vectors provided in the toolkit.
| 5' Entry Vectors | Description | Use(s) | Figure(s) | Lab | Reference |
|---|---|---|---|---|---|
| p5E-CMVmin | minimal cytomegalovirus immediate early enhancer/promoter (CMVmin) from pcDNA3 | strong ubiquitous expression | 3,4,5 | Washbourne | |
| p5E-hPGK | human phosphoglycerate kinase (hPGK) promoter | ubiquitious expression | 6 | Stankunas | |
| p5E-EF1α/β-globin | frog translation elongation factor 1α (EF1α) enhancer fused to rabbit β-globin intron | semi-ubiquitous expression | Stankunas | [ | |
| p5E-EF1α/β-Actin | EF1α/β-globin fused to zebrafish β-actin 2 enhancer/promoter | strong semi-ubiquitous expression | Stankunas | ||
| p5E-hSyn1 | human Synapsin1 (hSyn1) promoter | pan-neuronal expression | Washbourne | ||
| p5E-ESyn1 | hSyn1 promoter fused to CMVmin | strong pan-neuronal expression | Washbourne | ||
| p5E- | zebrafish | pan-neuronal expression | Eisen | ||
| p5E- | zebrafish | glial-specific expression | Eisen | ||
| p5E- | zebrafish | expressed in primary and subset of secondary motorneurons, also expressed in VeLD | Eisen | [ | |
| p5E- | FGF-responsive regulatory element of the zebrafish | FGF-responding cells | Stankunas | [ | |
| p5E- | zebrafish | epidermis-specific expression | Stankunas | [ | |
| p5E-Ui4-eSIBR | human ubiquitin C promoter followed by intronically-expressed eSIBR cassette | ubiquitious expression, RNAi | 3 | Stankunas | |
| pME-eSIBR | intronically-expressed eSIBR cassette | RNAi | 3 | Washbourne | [ |
| pME-tdTomato | orange-red fluorophore | imaging | Eisen | ||
| pME-tdTomato no stop | tdTomato without stop codon | imaging, N-terminal conjugation | Eisen | ||
| pME-mKate2 no stop | red fluorophore without stop codon | imaging, N-terminal conjugation | Washbourne | ||
| pME-GFP-P2A | GFP without stop codon followed by porcine teschovirus-1 2A (P2A) "self-cleaving" peptide | imaging, bicistronic expression | Washbourne | ||
| pME-nlsGFP-P2A | nuclear localization signal fused to N-terminus of GFP (nlsGFP) without stop codon, followed by P2A | nuclear-targeted GFP, imaging, bicistronic expression | Washbourne | ||
| pME-memGFP-P2A | Fyn myristoylation domain fused to N-terminus of GFP (memGFP) without stop codon, followed by P2A | membrane-targeted GFP, imaging, bicistronic expression | 5 | Washbourne | |
| pME-BrainbowTEC | Brainbow-1.0 with fluorophores tdTomato-myc/EGFP/E2Crimson-HA | Cre-induced recombination for imaging, circuit tracing, cell mapping, lineage tracing | 2 | Eisen | |
| pME-FlEx switch | empty FlEx cassette containing two pairs of heterotypic, antiparallel | permits permenant, Cre-dependent inversion of inserted sequence | Eisen | ||
| pME-ERT2-Cre-ERT2 | tamoxifen-inducible estrogen receptor (ERT2) fused to both ends of Cre recombinase | tamoxifen-inducible Cre recombination | Stankunas | [ | |
| pME-GAL4-ERT2-VP16 | GAL4 fused to ERT2 and the VP16 transcriptional activation domain | tamoxifen-inducible UAS-promoted transgene expression | Stankunas | [ | |
| p3E-mKate2-HA no-pA | hemagluttanin (HA) epitope fused to C-terminus of mKate2 without pA | imaging, epitope labeling/purification | Washbourne | ||
| p3E-mKate2-myc no-pA | myc epitope fused to C-terminus of mKate2 without pA | imaging, epitope labeling/purification | Washbourne | ||
| p3E-GFP no-pA | GFP without pA | imaging | Washbourne | ||
| p3E-nlsGFP pA | nlsGFP with pA | nuclear-targeted GFP, imaging | 3 | Washbourne | |
| p3E-nlsGFP no-pA | nlsGFP without pA | nuclear-targeted GFP, imaging | 3 | Washbourne | [ |
| p3E-GFPmem pA | palmitoylation domain of human hRas fused to C-terminus of GFP (GFPmem) with pA | membrane-targeted GFP, imaging | Washbourne | ||
| p3E-GFPmem no-pA | GFPmem without pA | membrane-targeted GFP, imaging | Washbourne | ||
| p3E-CMVmin:GFP pA | CMVmin-promoted GFP with pA | imaging, bicistronic expression | Washbourne | ||
| p3E-CMVmin:GFP no-pA | CMVmin-promoted GFP without pA | imaging, bicistronic expression | Washbourne | ||
| p3E-CMVmin:nlsGFP pA | CMVmin-promoted nlsGFP with pA | nuclear-targeted GFP, imaging, bicistronic expression | Washbourne | ||
| p3E-CMVmin:nlsGFP no-pA | CMVmin-promoted nlsGFP without pA | nuclear-targeted GFP, imaging, bicistronic expression | Washbourne | ||
| p3E-CMVmin:GFPmem pA | CMVmin-promoted GFPmem with pA | membrane-targeted GFP, imaging, bicistronic expression | Washbourne | ||
| p3E-CMVmin:GFPmem no-pA | CMVmin-promoted GFPmem without pA | membrane-targeted GFP, imaging, bicistronic expression | Washbourne | ||
| p3E-GFP-HA no-pA | HA epitope fused to C-terminus of GFP without pA | imaging, epitope labeling/purification | Stankunas | ||
| p3E-YFP-HA no-pA | HA epitope fused to C-terminus of YFP without pA | imaging, epitope labeling/purification | Stankunas | ||
| p3E-CFP-HA no-pA | HA epitope fused to C-terminus of CFP without pA | imaging, epitope labeling/purification | Stankunas | ||
| p3E-mCherry-HA no-pA | HA epitope fused to C-terminus of mCherry without pA | imaging, epitope labeling/purification | Stankunas | ||
| p3E-HA no-pA | HA epitope without pA | epitope labeling/purification | 3 | Stankunas | |
| p3E-P2A-MCS no-pA | P2A followed by multiple cloning site without pA | bicistronic expression | Washbourne | ||
| p3E-P2A-GFP no-pA | P2A followed by GFP without pA | imaging, bicistronic expression | 4 | Washbourne | |
| p3E-P2A-CFP no-pA | P2A followed by CFP without pA | imaging, bicistronic expression | Washbourne | ||
| p3E-P2A-mKate2 no-pA | P2A followed by mKate2 without pA | imaging, bicistronic expression | 4 | Washbourne | |
| p3E-FRB-HA no-pA | HA epitope fused to C-terminus of TOR FKBP and rapamycin binding (FRB) domain without pA | Rapamycin/rapalog-induced dimerization (with FKBP) | Stankunas | ||
| p3E-mCherry-FRB-HA no-pA | HA epitope fused to C-terminus and mCherry fused to N-terminus of FRB without pA | Rapamycin/rapalog-induced dimerization (with FKBP) | 7 | Stankunas | |
| p3E-FRB(KTF)-HA no-pA | HA epitope tag fused to C-terminus of FRB mutant (W2101F) without pA | Rapamycin/rapalog-induced dimerization (with FKBP) | Stankunas | ||
| p3E-FRB(PLF)-HA no-pA | HA epitope tag fused to C-terminus of FRB mutant (K2095P, T2098L, W2101F) without pA | Rapamycin/rapalog-induced dimerization (with FKBP) | Stankunas | ||
| p3E-FKBP-HA no-pA | HA epitope tag fused to C-terminus of human FK506 binding protein 12 (FKBP12) without pA | Rapamycin/rapalog-induced dimerization (with FRB) | Stankunas | ||
| p3E-SGTAP no-pA | streptavidin binding protein (SBP) followed by a TEV cleavage site and 2 protein G copies without pA | tandem affinity protein purification | 6 | Stankunas | |
| p3E-Dam-myc no-pA | myc epitope tag fused to C-terminus of | DamID for identifying native DNA binding sites of chromatin proteins | Stankunas | ||
| p3E- | FLP-induced kanamycin resistance, drug selection | Stankunas |
Fig 2Overview of pME-BrainbowTEC and application in developing zebrafish spinal cord.
(A) Schematic of pME-BrainbowTEC. (B) No recombination, loxP recombination or lox2272 recombination lead to distinct fluorophore expression. (C) Schematic of LR recombination reaction used to create UAS:BrainbowTEC. (D) Possible fluorophore combinations and resulting observed color from three copy expression of UAS:BrainbowTEC. (E) Experimental design for UAS:BrainbowTEC labeling of motoneurons in developing zebrafish spinal cords. Fish carrying multiple copies of UAS:BrainbowTEC were crossed with a dual inducible-Cre and motoneuron-specific GAL4 driver line (mnx1:GAL4; hsp70l:Cre). Embryos were heat-shocked at 7 hours post fertilization (hpf) to induce Cre expression for lox recombination of genomic UAS:BrainbowTEC copies, then imaged at 48 hpf. (F) Representative fluorescent confocal microscope image for GFP, tdTomato, and E2Crimson in 48 hpf zebrafish embryo showing neuronal cell bodies in the spinal cord and motor axons within several adjacent somites. Inset shows neuronal cell bodies in the spinal cord.
Fig 3Creation and optimization of potent multi-target lentiviral knockdown constructs using eSIBR-based artificial miRNA vectors.
(A) Schematic of LR recombination reactions used to create pEpic_Lite mCMV:eSIBR-nlsGFP pA and no-pA vectors. (B) Lentiviral titers obtained from mCMV:eSIBR-nlsGFP vectors with or without a pA signal sequence. Number of biological replicates (n) are shown on or above the bars. (C) Schematic of LR recombination reaction used to create pEpic_Lite UbiC:eSIBR-nlsGFP no-pA vectors. pME-nlsGFP contains a stop codon so the HA epitope in p3E-HA no-pA is not expressed. (D) Mean GFP intensity as measured by flow cytometry of HEK293T cells infected at single-copy levels with UbiC or CMVmin-promoted eSIBR vectors carrying scrambled1-3 or cadm1-3 amiRNAs. For scrambled1-3 and cadm1-3 groups, GFP intensity was set relative to UbiC-promoted GFP levels at an arbitrary value of 1 (dashed line). n = 3 biological replicates. (E) Representative quantitative western blots for antibodies against Cadm1, Cadm3, or Cadm1-3 and (F) quantification of protein knockdown from 14DIV cultured hippocampal neurons infected with lentivirus carrying amiRNAs against cadm1-3 compared to corresponding scrambled1-3 amiRNA infected control neurons. Number of biological replicates (n) is noted on or above bars. (G) Quantification of nlgn1, 2 and 3 mRNA levels by qRT-PCR from 14DIV cultured hippocampal neurons infected at saturating levels with lentivirus carrying a pEpic_Lite mCMV:eSIBR no-pA vector with amiRNAs against nlgn1, 2 and 3. mRNA levels were set relative to control sister cultures infected with a construct carrying scrambled1-3 amiRNAs (dashed line). (B,D,F,G) *p<0.05, **p<0.01 and ***p<0.001; Student’s two-tailed t-tests.
Fig 4Efficient bicistronic expression from C-terminal P2A conjugation.
(A) Schematic of LR recombination reaction used to create pEpic_Lite mCMV:ErbB3-P2A-GFP. (B) Western blots of COS7 cell lysates 48 hours after co-transfection with ErbB3-P2A-GFP and ErbB2-myc, with or without treatment with neuregulin. Immunoblotting was performed with antibodies against phosphorylated ErbB3 (pErbB3) or GFP.
Fig 5Effective dual protein expression through N-terminal P2A conjugation to HA-Neuroligin1.
(A) Schematic of LR recombination reaction used to create pEpic_Lite mCMV:memGFP-P2A-HA-Neuroligin1. (B) Dual fluorescent western blot of COS7 cell lysate 24 hours after transfection with mCMV:memGFP-P2A-HA-Neuroligin1. Immunoblotting was performed with antibodies against GFP and HA. (C) Immunocytochemistry for GFP and HA in COS7 cells 24 hours after transfection with mCMV:memGFP-P2A-HA-Neuroligin1. Cells were fixed with paraformaldehyde and surface stained for HA, then permeabilized and stained for GFP. (D) Immunocytochemistry for GFP, HA and the synaptic vesicle-associated protein Synapsin1 in cultured rat hippocampal neurons. Cells were transduced with lentivirus carrying mCMV:memGFP-P2A-HA-Neuroligin1at 2DIV and fixed for immunolabeling at 14DIV. Cells were surface stained for HA, then permeabilized and stained for GFP and Synapsin1. Inset is of an individual basal dendrite segment; the GFP mask is a binarized image of the dendrite using intensity thresholding of the GFP signal. Arrowheads mark dendritic spines containing HA and co-localized Synapsin1 puncta. Scale bar = 10 μm.
Fig 6Tandem affinity purification of chromatin-remodeling complex protein Baf57c using SGTAP.
(A) Schematic of LR recombination reaction used to create pEpic CMV:Baf57c-SGTAP. (B) Schematic of steps for TAP of Baf57-SGTAP. Step 1: Baf57c with a C-terminally conjugated SBP, TEV protease cleavage site, and tandem copies of protein G is first isolated by affinity purification using IgG-sepharose beads; Step 2: Baf57c-SBP is cleaved from protein G bound to IgG-sepharose beads by the addition of TEV protease; Step 3: Baf57c-SBP is further isolated by affinity purification using streptavidin-sepharose beads; Step 4: Baf57c-SBP is finally eluted from streptavidin by the addition of biotin. (C) Western blot for SBP at various stages of Baf57c purification from nuclear extracts of HEK293T cells expressing pEpic CMV-Baf57c-SGTAP. 10% of each indicated fraction was used for immunoblotting. Lane 1: the crude nuclear extract; Lane 2: nuclear extract after incubation with IgG beads; Lane 3: post-TEV protease cleavage of proteins bound to IgG beads; Lane 4: SDS elution of proteins from beads following Streptavidin purification. The asterisk indicates Baf57c-SGTAP fusion proteins; the arrow indicates the cleaved Baf57c-SBP fusion; molecular weights in kilodaltons are shown at the right.
Fig 7Rapamycin-induced dimerization to drive nuclear export.
(A) Schematic of LR recombination reaction used to create pEpic CMV:OGT1-mCherry-FRB-HA. (B) Schematic of rapamycin-induced dimerization with FKBP-NES to drive nuclear export. (C) Time-lapse imaging (S1 Movie) of mCherry in HEK293T cells transfected with pEpic CMV:OGT1-mCherry-FRB-HA and FKBP-NES. Rapamycin was added at time 0. White arrows mark cell nuclei.